CO2020008231A2 - Formulaciones inyectables de toxina botulínica y métodos de uso de las mismas que tienen una alta tasa de respuesta y una larga duración del efecto - Google Patents

Formulaciones inyectables de toxina botulínica y métodos de uso de las mismas que tienen una alta tasa de respuesta y una larga duración del efecto

Info

Publication number
CO2020008231A2
CO2020008231A2 CONC2020/0008231A CO2020008231A CO2020008231A2 CO 2020008231 A2 CO2020008231 A2 CO 2020008231A2 CO 2020008231 A CO2020008231 A CO 2020008231A CO 2020008231 A2 CO2020008231 A2 CO 2020008231A2
Authority
CO
Colombia
Prior art keywords
effect
botulinum toxin
methods
response rate
long duration
Prior art date
Application number
CONC2020/0008231A
Other languages
English (en)
Inventor
Roman Rubio
Original Assignee
Revance Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Revance Therapeutics Inc filed Critical Revance Therapeutics Inc
Publication of CO2020008231A2 publication Critical patent/CO2020008231A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/66—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/56—Compounds, absorbed onto or entrapped into a solid carrier, e.g. encapsulated perfumes, inclusion compounds, sustained release forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Peptides Or Proteins (AREA)

Abstract

RESUMEN Esta invención proporciona composiciones inyectables que comprenden toxina botulínica que pueden administrarse a un sujeto para diversos fines terapéuticos, estéticos y/o cosméticos. Las composiciones inyectables incluidas en la invención exhiben una o más ventajas sobre las formulaciones convencionales de toxina botulínica, que incluyen una antigenicidad reducida, una tendencia reducida a experimentar difusión localizada no deseada después de la inyección, una mayor duración de la eficacia clínica o una potencia mejorada, tasas de respondedores más altas, inicio más rápido de la eficacia clínica y/o estabilidad mejorada. De acuerdo con la invención, el tratamiento único de las composiciones por inyección proporciona respuestas clínicas significativas y al menos una duración de efecto de 26 semanas en un sujeto sometido a tratamiento, tal como se proporciona mediante los métodos de tratamiento descritos, así como tasas de respuesta y/o una duración del efecto más larga después de tratamientos subsecuentes.
CONC2020/0008231A 2017-12-04 2020-07-02 Formulaciones inyectables de toxina botulínica y métodos de uso de las mismas que tienen una alta tasa de respuesta y una larga duración del efecto CO2020008231A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762594529P 2017-12-04 2017-12-04
US201862774850P 2018-12-03 2018-12-03
PCT/US2018/063942 WO2019113133A1 (en) 2017-12-04 2018-12-04 Injectable botulinum toxin formulations and methods of use thereof having high response rate and long effect duration

Publications (1)

Publication Number Publication Date
CO2020008231A2 true CO2020008231A2 (es) 2020-08-10

Family

ID=66750627

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2020/0008231A CO2020008231A2 (es) 2017-12-04 2020-07-02 Formulaciones inyectables de toxina botulínica y métodos de uso de las mismas que tienen una alta tasa de respuesta y una larga duración del efecto

Country Status (15)

Country Link
US (1) US20200384090A1 (es)
EP (1) EP3720475A4 (es)
JP (1) JP2021505570A (es)
KR (1) KR20200105829A (es)
CN (1) CN111655279A (es)
AU (1) AU2018378465A1 (es)
BR (1) BR112020011098A2 (es)
CA (1) CA3084175A1 (es)
CO (1) CO2020008231A2 (es)
IL (1) IL275032A (es)
MX (1) MX2020005785A (es)
PH (1) PH12020550821A1 (es)
RU (1) RU2020121540A (es)
SG (1) SG11202005239YA (es)
WO (1) WO2019113133A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL268980B (en) 2009-06-25 2022-09-01 Revance Therapeutics Inc Botulinum toxin formulations without albumin
US20200179498A1 (en) * 2017-05-18 2020-06-11 Revance Therapeutics, Inc. Methods of treatment for cervical dystonia
MX2022014564A (es) * 2020-06-05 2022-12-15 Merz Pharma Gmbh & Co Kgaa Tratamiento de arrugas faciales con toxina botulinica a dosis alta y volumen bajo.
EP4228599A1 (en) * 2020-10-13 2023-08-23 ReVance Therapeutics, Inc. Methods for treating cervical dystonia
CN117693366A (zh) * 2021-02-21 2024-03-12 雷文斯治疗公司 用于治疗上肢痉挛的方法和组合物
CN113432267A (zh) * 2021-06-29 2021-09-24 哈尔滨蛐宝科技有限公司 一种基于wifi的空气消毒智能控制方法和装置
KR20240047418A (ko) * 2021-08-12 2024-04-12 이온 바이오파마, 인크. 일회용 신경독 제형 및 패키징

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9180081B2 (en) * 2005-03-03 2015-11-10 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
US8518414B2 (en) * 2005-11-17 2013-08-27 Revance Therapeutics, Inc. Compositions and methods of topical application and transdermal delivery of botulinum toxins with reduced non-toxin proteins
JP5866202B2 (ja) * 2008-12-31 2016-02-17 ルバンス セラピュティックス インク．Ｒｅｖａｎｃｅ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 注射用ボツリヌス毒素製剤
US20140242110A1 (en) * 2013-02-28 2014-08-28 Dt Scimed, Llc Dose, localization, and formulation of botulinum toxins in skin and muscle
US9480731B2 (en) * 2013-12-12 2016-11-01 Medy-Tox, Inc. Long lasting effect of new botulinum toxin formulations
US20160166703A1 (en) * 2014-12-08 2016-06-16 JJSK R&D Pte Ltd Carrier Molecule Compositions and Related Methods
SG10202004337WA (en) * 2015-10-29 2020-06-29 Revance Therapeutics Inc Injectable botulinum toxin formulations and methods of use thereof having long duration of therapeutic or cosmetic effect

Also Published As

Publication number Publication date
BR112020011098A2 (pt) 2020-11-17
SG11202005239YA (en) 2020-07-29
US20200384090A1 (en) 2020-12-10
EP3720475A4 (en) 2021-09-08
CA3084175A1 (en) 2019-06-13
CN111655279A (zh) 2020-09-11
JP2021505570A (ja) 2021-02-18
KR20200105829A (ko) 2020-09-09
RU2020121540A3 (es) 2022-04-27
IL275032A (en) 2020-07-30
AU2018378465A1 (en) 2020-07-09
MX2020005785A (es) 2020-10-28
PH12020550821A1 (en) 2021-05-10
RU2020121540A (ru) 2022-01-10
EP3720475A1 (en) 2020-10-14
WO2019113133A1 (en) 2019-06-13

Similar Documents

Publication Publication Date Title
CO2020008231A2 (es) Formulaciones inyectables de toxina botulínica y métodos de uso de las mismas que tienen una alta tasa de respuesta y una larga duración del efecto
BR112018008684A2 (pt) formulações de toxina botulínica injetáveis e processos de uso das mesmas com longa duração do efeito terapêutico ou cosmético
CO2017011536A2 (es) Composiciones que comprenden una combinación de un anticuerpo anti muerte programada 1 (pd-1) y otro anticuerpo
CO2017004715A2 (es) Métodos y formulaciones para tratar enfermedades vasculares de los ojos
SV2016005320A (es) Formulaciones y mã‰todos de tratamiento con queratina
UY36665A (es) Derivados de ciclohexano sustituidos con amidas
CL2019003589A1 (es) Derivado de n2,n4-difenilpirimidin-2,4-diamina, método para la preparación del mismo, y una composición farmacéutica que contiene el mismo como ingrediente activo para la prevención o tratamiento de cáncer.
BR112018074450A2 (pt) composições e métodos para a utilização de nintedanib para melhorar o sucesso da cirurgia do glaucoma
MX2011007059A (es) Formulaciones inyectables de toxinas de botulino.
CL2020000220A1 (es) Composiciones que comprenden aminoácidos para su uso en el tratamiento de enfermedades relacionadas con la disfunción mitocondrial.
CL2022000194A1 (es) Uso para tratar la enfermedad de hemorragia alveolar difusa asociada con trasplante de células madre hematopoyéticas (divisional de la solicitud no. 202000384)
BR112018002530A2 (pt) combinações e usos e tratamentos destas
CR20140475A (es) Agentes terapéuticos para administración subcutánea optimizados
CO6660486A2 (es) Composición tópica famacéutica o cosmética útil para el tratamiento de enfermedades o condiciones que cursan con un déficit de la maduración de la envoltura córnea
CO2018012180A2 (es) Métodos de tratamiento para enfermedades colestásicas y fibróticas
CO2019008053A2 (es) Agente terapéutico para enfermedades del hígado
MX2020004516A (es) Metodos y composiciones para la dosificacion de celulas t con receptor de antigeno quimerico alogenicas.
ECSP12011967A (es) Métodos y composiciones para el tratamiento rápido de otitis externa
UY37577A (es) Dihidroimidazopiridindionas sustituidas
MX2018007871A (es) Composiciones para el cuidado personal.
CO2017003263A2 (es) Composición farmacéutica basadas en anamorelina que tienen actividad sobre caquexia causada por cáncer
AR102778A1 (es) Composición farmacéutica, su preparación y sus usos
BR112015022196A2 (pt) composições de liberação prolongada, que compreendem hidrocodona e acetaminofeno para rápido início e analgesia prolongada, que podem ser administradas independentemente de alimentos
MX2020001428A (es) Composiciones de grapiprant y metodos para usar las mismas.
PE20200746A1 (es) AGENTES DE iARN PARA LA INHIBICION DE LA EXPRESION DE ALFA-ENAC Y METODOS DE USO